MX384604B - Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes. - Google Patents

Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.

Info

Publication number
MX384604B
MX384604B MX2020010847A MX2020010847A MX384604B MX 384604 B MX384604 B MX 384604B MX 2020010847 A MX2020010847 A MX 2020010847A MX 2020010847 A MX2020010847 A MX 2020010847A MX 384604 B MX384604 B MX 384604B
Authority
MX
Mexico
Prior art keywords
sup
sub
imaging agents
salts
heterocyclic compounds
Prior art date
Application number
MX2020010847A
Other languages
English (en)
Spanish (es)
Other versions
MX2020010847A (es
Inventor
Jan Marik
Joseph P Lyssikatos
Simon Williams
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020010847A publication Critical patent/MX2020010847A/es
Publication of MX384604B publication Critical patent/MX384604B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2020010847A 2014-05-13 2015-05-12 Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes. MX384604B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461992717P 2014-05-13 2014-05-13
PCT/EP2015/060447 WO2015173225A1 (en) 2014-05-13 2015-05-12 Deuterated heterocyclic compounds and their use as imaging agents

Publications (2)

Publication Number Publication Date
MX2020010847A MX2020010847A (es) 2021-07-16
MX384604B true MX384604B (es) 2025-03-14

Family

ID=53269446

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020010847A MX384604B (es) 2014-05-13 2015-05-12 Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.
MX2016014615A MX376163B (es) 2014-05-13 2015-05-12 Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016014615A MX376163B (es) 2014-05-13 2015-05-12 Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.

Country Status (21)

Country Link
US (4) US10076581B2 (cg-RX-API-DMAC7.html)
EP (2) EP3143011B1 (cg-RX-API-DMAC7.html)
JP (2) JP6529986B2 (cg-RX-API-DMAC7.html)
KR (2) KR102618139B1 (cg-RX-API-DMAC7.html)
CN (2) CN110483522B (cg-RX-API-DMAC7.html)
AU (2) AU2015261008B2 (cg-RX-API-DMAC7.html)
CA (1) CA2948721C (cg-RX-API-DMAC7.html)
DK (1) DK3143011T3 (cg-RX-API-DMAC7.html)
ES (1) ES2867814T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210641T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053939T2 (cg-RX-API-DMAC7.html)
IL (3) IL280791B2 (cg-RX-API-DMAC7.html)
LT (1) LT3143011T (cg-RX-API-DMAC7.html)
MX (2) MX384604B (cg-RX-API-DMAC7.html)
PL (1) PL3143011T3 (cg-RX-API-DMAC7.html)
PT (1) PT3143011T (cg-RX-API-DMAC7.html)
RS (1) RS61810B1 (cg-RX-API-DMAC7.html)
RU (1) RU2696492C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201805628TA (cg-RX-API-DMAC7.html)
SI (1) SI3143011T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015173225A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110483522B (zh) 2014-05-13 2022-05-03 豪夫迈·罗氏有限公司 氘化杂环化合物和其作为成像剂的用途
WO2018015549A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
US10865207B2 (en) 2016-07-22 2020-12-15 Ac Immune S.A. Compounds for imaging Tau protein aggregates
JP7286539B2 (ja) * 2016-11-01 2023-06-05 アルビナス・オペレーションズ・インコーポレイテッド タウタンパク質標的化protac、および関連使用方法
KR102717600B1 (ko) 2017-10-06 2024-10-15 포르마 세라퓨틱스 인크. 유비퀴틴 특이적 펩티다제 30의 억제
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
US11623927B2 (en) 2018-03-02 2023-04-11 The Trustees Of The University Of Pennsylvania Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules
CA3098628A1 (en) 2018-05-17 2019-11-21 Forma Therapeutics, Inc. Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
WO2020061101A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
PT3860989T (pt) 2018-10-05 2023-06-30 Forma Therapeutics Inc Pirrolinas fundidas que atuam como inibidores da protease 30 específica da ubiquitina (usp30)
BR112021006488A2 (pt) 2018-10-05 2021-07-06 Annapurna Bio Inc compostos e composições para o tratamento de condições associadas com atividade do receptor apj
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
JP7119978B2 (ja) * 2018-12-20 2022-08-17 オムロン株式会社 制御装置およびプログラム
CA3138873C (en) * 2019-05-09 2024-01-09 Kyle Bradley Pascual CLAGG Synthesis of labeled imidazo[1,2-a]pyrimidines
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
CN113526526A (zh) * 2021-07-12 2021-10-22 苏州大学 氘代氨制备方法及以其作为氘源参与的氘代反应
CA3228359A1 (en) 2021-08-27 2023-03-02 Genentech, Inc. Methods of treating tau pathologies
EP4536358A1 (en) 2022-06-13 2025-04-16 Genentech Inc. Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
WO2025155625A1 (en) * 2024-01-16 2025-07-24 Eli Lilly And Company Novel compounds for tau imaging
CN118957609B (zh) * 2024-07-23 2025-09-09 无锡绿能电合科技有限公司 一种氟代芳环的氘代方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD76515A (cg-RX-API-DMAC7.html) *
DE76515C (de) F. MORA in Mailand Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff
EP1340759A1 (en) 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
SI2363392T1 (sl) 2006-03-30 2017-09-29 The Trustees Of The University Of Pennsylvania Center For Technology Transfer Derivati stirilpiridina in njihova uporaba za vezavo in prikazovanje amiloidnih plakov
AU2008299921B2 (en) * 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
CA2715390A1 (en) 2008-02-14 2009-08-20 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological dysfunction
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US20100144657A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
KR101316982B1 (ko) 2009-03-23 2013-10-15 일라이 릴리 앤드 캄파니 신경계 장애를 검출하기 위한 조영제
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
EP2450332A1 (en) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
AU2011331301A1 (en) * 2010-11-15 2013-05-23 Katholieke Universiteit Leuven Antiviral condensed heterocyclic compounds
KR101609504B1 (ko) * 2012-05-22 2016-04-05 일라이 릴리 앤드 캄파니 신경계 기능장애를 검출하기 위한 카르볼린계 및 카르바졸계 영상화제
SI3055308T1 (en) * 2013-10-08 2018-03-30 F. Hoffmann-La Roche Ag Diazacarbazole derivatives as tau-pet-ligands
CN110483522B (zh) 2014-05-13 2022-05-03 豪夫迈·罗氏有限公司 氘化杂环化合物和其作为成像剂的用途

Also Published As

Publication number Publication date
MX2020010847A (es) 2021-07-16
KR102530129B1 (ko) 2023-05-10
US10076581B2 (en) 2018-09-18
LT3143011T (lt) 2021-05-10
HUE053939T2 (hu) 2021-08-30
IL271631A (en) 2020-02-27
RU2016147742A (ru) 2018-06-18
HRP20210641T1 (hr) 2021-05-28
CN106459059A (zh) 2017-02-22
CA2948721C (en) 2023-03-28
RU2016147742A3 (cg-RX-API-DMAC7.html) 2018-10-08
AU2019203369A1 (en) 2019-06-06
CA2948721A1 (en) 2015-11-19
US20200297875A1 (en) 2020-09-24
IL280791A (en) 2021-04-29
ES2867814T3 (es) 2021-10-20
KR102618139B1 (ko) 2023-12-27
WO2015173225A1 (en) 2015-11-19
IL280791B1 (en) 2023-11-01
IL248692A0 (en) 2017-01-31
US20160250358A1 (en) 2016-09-01
JP6681498B2 (ja) 2020-04-15
AU2015261008A1 (en) 2016-11-17
RU2696492C2 (ru) 2019-08-02
SG10201805628TA (en) 2018-08-30
PT3143011T (pt) 2021-04-26
PL3143011T3 (pl) 2021-07-19
MX376163B (es) 2025-03-07
AU2015261008B2 (en) 2019-02-14
SG11201609281UA (en) 2016-12-29
US10675367B2 (en) 2020-06-09
US11504440B2 (en) 2022-11-22
BR112016026443A2 (pt) 2017-08-15
NZ764181A (en) 2023-11-24
US20230218782A1 (en) 2023-07-13
US12214058B2 (en) 2025-02-04
MX2016014615A (es) 2017-03-06
AU2019203369B2 (en) 2020-06-04
JP2019147825A (ja) 2019-09-05
CN110483522B (zh) 2022-05-03
DK3143011T3 (da) 2021-05-03
IL248692B (en) 2020-01-30
US20190201561A1 (en) 2019-07-04
BR112016026443A8 (pt) 2021-07-06
JP6529986B2 (ja) 2019-06-12
IL280791B2 (en) 2024-03-01
CN110483522A (zh) 2019-11-22
RS61810B1 (sr) 2021-06-30
EP3143011A1 (en) 2017-03-22
CN106459059B (zh) 2019-09-24
SI3143011T1 (sl) 2021-08-31
EP3901145A1 (en) 2021-10-27
EP3143011B1 (en) 2021-03-03
KR20230035445A (ko) 2023-03-13
KR20170002639A (ko) 2017-01-06
IL271631B (en) 2021-05-31
NZ726208A (en) 2023-11-24
JP2017515856A (ja) 2017-06-15

Similar Documents

Publication Publication Date Title
MX384604B (es) Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.
MX378155B (es) Derivados de 9h-pirrolo-dipiridina.
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
DOP2017000267A (es) Amidas heterocíclicas como inhibidores de quinasa
CL2017000654A1 (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
DK3743086T3 (da) Sammensætningner omfattende bakteriestammer
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
CR20140135A (es) Nuevos derivados de aril-quinolina
EP3911323A4 (en) HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EA201301334A1 (ru) Меченные радиоактивными изотопами ингибиторы глутаминилциклазы
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
EP3666770A4 (en) NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
EP3615525C0 (en) PYRROLE DERIVATIVES AS PLK1 INHIBITORS
EP3498275C0 (en) USE OF COMPOUNDS KNOWN AS D-AMINOACID OXIDASE INHIBITORS
MX374323B (es) Compuestos de heteroarilo y métodos de uso de los mismos.
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов
EP3802530C0 (en) HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS
WO2015102024A3 (en) Novel substituted 5 membered heterocyclic compounds and preparation thereof